Globus Medical (GMED) director Leslie Norwalk sells 2,000 shares via 10b5-1

Rhea-AI Filing Summary

Globus Medical director reports preset stock sale

Globus Medical director Leslie V. Norwalk reported selling 2,000 shares of the company’s Class A common stock on January 8, 2026 at a price of $101.10 per share. After this transaction, Norwalk beneficially owned 10,419 Class A shares, all held directly. The filing notes that the sale was made under a Rule 10b5-1 trading plan that was put in place on September 12, 2025, indicating the trades were pre-arranged rather than decided at the time of sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norwalk Leslie V

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/08/2026		S(1)		2,000	D	$101.1	10,419	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated September 12, 2025 executed by the reporting person.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Globus Medical (GMED) report for January 8, 2026?

On January 8, 2026, director Leslie V. Norwalk sold 2,000 shares of Globus Medical Class A common stock at $101.10 per share, as disclosed in a Form 4 filing.

How many Globus Medical (GMED) shares does Leslie V. Norwalk own after the reported sale?

Following the January 8, 2026 transaction, Leslie V. Norwalk beneficially owns 10,419 shares of Globus Medical Class A common stock, held directly.

Was the January 8, 2026 GMED insider sale under a Rule 10b5-1 plan?

Yes. The filing explains that the 2,000-share sale on January 8, 2026 was effectuated under a Rule 10b5-1 trading plan dated September 12, 2025 and executed by the reporting person.

Who is the insider involved in the latest Globus Medical (GMED) stock sale?

The insider is Leslie V. Norwalk, who is identified in the filing as a director of Globus Medical and the reporting person for the January 8, 2026 stock sale.

Is the Globus Medical (GMED) insider transaction a direct or indirect holding change?

The Form 4 indicates that the 2,000-share sale and the remaining 10,419 shares are reported as direct (D) ownership by Leslie V. Norwalk, with no indirect ownership entity listed.

What type of security did the Globus Medical (GMED) director sell in this filing?

The transaction involved Class A common stock of Globus Medical, with 2,000 shares sold at a price of $101.10 per share on January 8, 2026.